COMPANY UPDATES
11
Mar
2020
Novoheart Holdings Inc. Reports Second Quarter and Fiscal 2019 Financial Results

Novoheart Holdings Inc.reports financial results for the three months ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).

20
Feb
2020
Novoheart Named 2020 Venture 50 Company Ranked Among Year’s Top Performing Stocks in Life Sciences

Novoheart is pleased to announce that it has been named a 2020 Venture 50 Company, ranked among the TSX Venture Exchange’s top 50 best performing companies

21
Jan
2020
Novoheart Contracts with Global Pharma to Develop Novel Microplate for High Throughput Drug Screening Using Engineered Human Heart Tissue Strips

Novoheart is pleased to announce the completion of a research and development contract sponsored by a top 10 global pharma. The contract deliverables will see Novoheart further expand its current testing capabilities of the MyHeartTM Platform by designing and developing a new versatile High-Throughput microplate which will allow the screening of hundreds of drugs using engineered human ventricular Cardiac Tissue Strips (hvCTS).

07
Jan
2020
Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies

Novoheart has been awarded a further grant from the Innovation and Technology Commission (ITC) of Hong Kong SAR Government. Combined with a cash rebate scheme and funding for hiring R&D talent, the Company is expected to receive a total of over HK$10 million ($1.67 million CAD) in grant awards from the ITC over the next 2 years.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!